← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2004First marketed drug
Jun 27, 2012First NDA
Jun 27, 2012Last known activity
Feb 12, 2025
Acquired by Pfizer on Dec 13, 2021
Timeline
1970s
- Jan 1, 1977
Arena Pharmaceuticals— Founded
2010s
- Jun 27, 2012
lorcaserin— NDA Organization
2020s
- Dec 13, 2021
Pfizer— Acquired By
Drugs by trial phase (11 distinct, 52 trials)
Indications
Approved for
Studied for
- Abdominal Pain
- Alopecia
- Alopecia Areata
- Cardiovascular Diseases
- Cataplexy
- Cholangitis
- Colitis
- Colitis, Ulcerative
- Connective Tissue Diseases
- Crohn Disease
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus
- Eczema
- Eosinophilic Esophagitis
- Esophagitis
- Familial Primary Pulmonary Hypertension
- Hypertension
- Hypertension, Pulmonary
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Irritable Bowel Syndrome
- Liver Cirrhosis, Biliary
- Liver Diseases
- Lung Diseases
- Narcolepsy
- Obesity
- Overweight
- Pyoderma
- Pyoderma Gangrenosum
- Renal Insufficiency
- Respiratory Tract Diseases
- Sleep Initiation and Maintenance Disorders
- Substance-Related Disorders
- Syndrome
- Ulcer
- Vascular Diseases
Marketed drugs (1)
Recent trials (50)
- NCT06149663Lead sponsorN/A—
- NCT06908226Lead sponsorPhase 3Feb 12, 2025
- NCT06719141Lead sponsorPhase 3Nov 11, 2024
- NCT06660394Lead sponsorPhase 3Oct 2, 2024
- NCT05287126Lead sponsorPhase 2Jan 15, 2023
- NCT05626634Lead sponsorPhase 2Nov 8, 2022
- NCT05364021Lead sponsorPhase 1/Phase 2Mar 3, 2022
- NCT05139615Study directorPhase 2Nov 30, 2021
- NCT05139615Lead sponsorPhase 2Nov 30, 2021
- NCT05061446Lead sponsorPhase 2Oct 16, 2021
- NCT05061446Study directorPhase 2Oct 16, 2021
- NCT05033340CollaboratorPhase 2/Phase 3Sep 1, 2021
- NCT05033340Lead sponsorPhase 2/Phase 3Sep 1, 2021
- NCT04915950Lead sponsorPhase 2Aug 31, 2021
- NCT04915950Study directorPhase 2Aug 31, 2021
Details
- Founded
- San Diego, CA, US Jan 1, 1977
- First NDA
- Jun 27, 2012
- Last known activity
- Feb 12, 2025